Get started
Author

Karim Hussien El-Shakankery

Observed names: El-Shakankery, Karim, K El-Shakankery, K H El-Shakankery, K. EL-Shakankery, K. El-Shakankery, K.H. El-Shakankery, Karim El Shakankery, Karim El-Shakankery, Karim H El-Shakankery, Karim H. El-Shakankery, Karim Hussien El‐Shakankery
Institutions: NHS Lothian, Western General Hospital, Cancer Research UK, Edinburgh Cancer Research, Institute of Genetics and Cancer, University of Edinburgh
Observed institutions: University College Hospital, St Bartholomew's Hospital, NHS Lothian, University College London Hospitals NHS Foundation Trust, University of Aberdeen, Barts Health NHS Trust, Western General Hospital, Royal London Hospital, Cancer Research UK, Edinburgh Cancer Research, Homerton University Hospital, Whipps Cross University Hospital, Queen's Hospital, Institute of Genetics and Cancer, University College London, University of Edinburgh
ORCID: 0000-0002-7516-1541
Observed ORCID: 0000-0002-7516-1541
OpenAlex ID: A5010728063
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 1,976
PDF
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533
PDF
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129
PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
2022 · Rowan E Miller, Karim H El-Shakankery, et al. · Journal of Gynecologic Oncology · 54
PDF
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41
PDF
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39
PDF
Caring for our cancer patients in the wake of COVID-19
2020 · Karim Hussien El-Shakankery, Joanna Kefas, et al. · British Journal of Cancer · 34
PDF
Desmoplasia and Biophysics in Pancreatic Ductal Adenocarcinoma
2020 · Francesco Di Maggio, Karim Hussien El-Shakankery · Pancreas · 31
Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
2022 · Rowan E Miller, Osnat Elyashiv, et al. · OncoTargets and Therapy · 28
PDF
Ratio of Oxygen Saturation Index to Guide Management of COVID-19 Pneumonia
2021 · Douglas L. Fink, Nina R. Goldman, et al. · Annals of the American Thoracic Society · 24
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
2023 · Rebecca Newhouse, Ellen Nelissen, et al. · Cochrane Database of Systematic Reviews · 19
PDF
Development and internal validation of a diagnostic prediction model for COVID-19 at time of admission to hospital
2020 · D L Fink, P Y Khan, et al. · QJM · 18
PDF
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12
PDF
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma
2024 · Bernardo Stefanini, Giulia F. Manfredi, et al. · Expert Review of Gastroenterology & Hepatology · 8
Targeting HPV in gynaecological cancers – Current status, ongoing challenges and future directions
2020 · Shanthini M Crusz, Karim El-Shakankery, et al. · Women s Health · 8
PDF
UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer
2026 · J. McKeon, E. Daniels, et al. · ESMO Real World Data and Digital Oncology · 5
PDF
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5
Panton–Valentine leucocidin Staphylococcus aureus necrotising pneumonia in a clinically well patient
2023 · Rebecca Newell, Karim El-Shakankery, et al. · British Journal of Hospital Medicine · 3
COVID-19, the Future Vaccine and What It Means for Cancer Patients on Immunotherapy
2021 · Karim Hussien El-Shakankery, Joanna Kefas, et al. · Frontiers in Oncology · 3
PDF
A key role for comprehensive geriatric assessment in aortic valve replacement
2020 · Karim Hussien El-Shakankery, Luis Mieiro · BMJ Case Reports · 3
Case report: A rare case of immunotherapy induced isolated left CN VI palsy in a patient with unresectable melanoma
2024 · Samantha Su Ping Low, Karim El-Shakankery, et al. · Frontiers in Oncology · 2
PDF
Works count: 44
Citation count: 2,477
H-index: 15
I10-index: 16
Year
Topic
Type